Fairmount Funds Management
Fairmount Funds Management reported 12 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ORKA (19.4%), KRSA (18.3%) and DNTH (14.0%). Compared with Q2 2026, the fund opened new positions in KRSA and DMRA and added to ZBIO and CBIO.
Latest filing: what Fairmount Funds Management did in Q3 2026
vs Q2 2026None
- Galecto Inc$227M
- Apogee Therapeutic$39.6M
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() ORKA Oruka Therapeutics Inc | $309M | 19.4% | 3.7M | No change | 8 of 8 | |
| 2 | ![]() KRSA Korsana Biosciences Inc | $291M | 18.3% | 9.1M | New position | 1 of 8 | |
| 3 | ![]() DNTH Dianthus Therapeutics Inc | $223M | 14.0% | 2.5M | No change | 8 of 8 | |
| 4 | ![]() DMRA Damora Therapeutics Inc | $185M | 11.6% | 8.7M | New position | 1 of 8 | |
| 5 | ![]() COGT Cogent Biosciences Inc | $176M | 11.1% | 5.5M | No change | 8 of 8 | |
| 6 | ![]() VRDN Viridian Therapeutics Inc | $105M | 6.6% | 5.1M | No change | 8 of 8 | |
| 7 | ![]() ELVN Enliven Therapeutics Inc | $85.1M | 5.3% | 1.9M | No change | 8 of 8 | |
| 8 | ![]() JBIO Jade Biosciences Inc | $64M | 4.0% | 4.6M | No change | 6 of 8 | |
| 9 | ![]() ZBIO Zenas Biopharma Inc | $64M | 4.0% | 2.4M | +12K (+1%) | 8 of 8 | |
| 10 | ![]() CBIO Crescent Biopharma Inc. | $52.5M | 3.3% | 3.6M | +853K (+31%) | 6 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
GALECTO INC | $227M | 8.7M |
APOGEE THERAPEUTICS INC | $39.6M | 299K |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Fairmount Funds Management 13F FAQ
What does Fairmount Funds Management own?
Fairmount Funds Management reported 12 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ORKA (19.4%), KRSA (18.3%) and DNTH (14.0%). The table above lists every position in the filing (the top 10 without an account).
What did Fairmount Funds Management buy and sell in Q3 2026?
Compared with Q2 2026: 2 new positions, 2 added to, 0 trimmed and 2 sold out. New positions include KRSA and DMRA.
When will Fairmount Funds Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Fairmount Funds Management's portfolio worth?
The Q3 2026 filing reports $1.6B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.









